InterCure Bilan de santé

Santé financière contrôle des critères 3/6

InterCure possède un total de capitaux propres de ₪462.1M et une dette totale de ₪133.1M, ce qui porte son ratio d'endettement à 28.8%. Son actif total et son passif total sont ₪740.9M et de ₪278.8M.

Informations clés

28.8%

Ratio d'endettement

₪133.07m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	₪20.30m
Fonds propres	₪462.12m
Total du passif	₪278.77m
Total des actifs	₪740.89m

Mises à jour récentes de la santé financière

Recent updates

InterCure Chairman Ehud Barak, CEO Alex Rabinovitch - Israel Cannabis And Beyond (Video)

Nov 08

InterCure: Internationally Profitable Cannabis (Podcast Transcript)

Sep 19

InterCure: Ignored Uplisting

Sep 09

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de INCR ( ₪370.8M ) dépassent ses passifs à court terme ( ₪208.9M ).

Passif à long terme: Les actifs à court terme de INCR ( ₪370.8M ) dépassent ses passifs à long terme ( ₪69.9M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de INCR ( 24.4% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de INCR est passé de 5% à 28.8% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: Données insuffisantes pour déterminer si INCR dispose de suffisamment de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: Données insuffisantes pour déterminer si INCR dispose de suffisamment de piste de trésorerie si son flux de trésorerie disponible continue de croître ou de diminuer en fonction des taux historiques.

InterCure Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

InterCure Ltd. announced delayed 20-F filing

InterCure Announces Proposed Voluntary Delisting from the Toronto Stock Exchange

InterCure Announces Proposed Voluntary Delisting from the Toronto Stock Exchange

Recent updates

InterCure: A Cannabis Industry Leader Still Flying Under The Radar

InterCure Ltd. announced delayed 20-F filing

InterCure: Bargain Israel Cannabis Play

InterCure Ltd. Announces Resignation of Rami Levy as Chief of Operations

InterCure Ltd., Annual General Meeting, Dec 14, 2023

InterCure Ltd. Wins Cannolam Arbitration Proceeding

InterCure Announces Proposed Voluntary Delisting from the Toronto Stock Exchange

InterCure Announces Proposed Voluntary Delisting from the Toronto Stock Exchange

Better Files A Lawsuit Against InterCure and its Chairman Ehud Barak

Investor sentiment improves as stock rises 16%

Price target decreased by 50% to US$5.00

First quarter 2023 earnings released: EPS: ₪0.005 (vs ₪0.38 in 1Q 2022)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorated over the past week

InterCure Ltd. Announces the Withdrawal of Class Action Lawsuit Against It

InterCure Ltd. (TASE:INCR) entered into an agreement to acquire 51% stake in Orni Pharmacy Ltd.

Intercure Provides Revenue Guidance for Fourth Quarter 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

InterCure: A Leader In Global Cannabis

Second quarter 2022 earnings: EPS misses analyst expectations

InterCure reports Q2 results

InterCure Ltd. to Report Q2, 2022 Results on Aug 15, 2022

InterCure Ltd. Announces Revenue Guidance for the Second Quarter of 2022

InterCure Ltd., Annual General Meeting, Sep 15, 2022

InterCure Is Growing In The Massive Global Cannabis Market

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

InterCure Ltd. Provides Revenue Guidance for the Second Quarter and Full Year of 2022

InterCure Ltd. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Now 23% undervalued

Intercure Ltd. Provides Revenue Results Fourth Quarter and Fiscal Year 2021

InterCure Ltd. to Report Q4, 2021 Results on Mar 31, 2022

Insider recently sold US$427k worth of stock

Investor sentiment improved over the past week

Less than half of directors are independent

IntureCure: Israel Recreation Cannabis Boom On The Way

Investor sentiment improved over the past week

Intercure Ltd. Provides Preliminary Earnings Guidance for the Fourth Quarter and Fiscal Year 2021 and Fiscal Year 2022

Third quarter 2021 earnings released: ₪0.04 loss per share (vs ₪0.067 profit in 3Q 2020)

Investor sentiment improved over the past week

InterCure Chairman Ehud Barak, CEO Alex Rabinovitch - Israel Cannabis And Beyond (Video)

InterCure: Internationally Profitable Cannabis (Podcast Transcript)

Price target increased to US$10.00

Less than half of directors are independent

Price target increased to US$10.00

Less than half of directors are independent

InterCure: Ignored Uplisting

Price target increased to US$10.00

Less than half of directors are independent

Price target increased to US$10.00

Less than half of directors are independent

InterCure Ltd. (TASE:INCR) entered into an agreement to acquire Max Pharm/Hello Pharm/A Pharmacy from Cannomed Medical Cannabis Industries LTD (TASE:CNMD).

Less than half of directors are independent

Price target increased to US$10.00

Investor sentiment improved over the past week

InterCure Ltd. (TASE:INCR) agreed to acquire better of Cann Pharmaceutical Ltd.

InterCure Ltd (TASE:INCR) signed a definitive agreement to acquire Licensed active medical cannabis trading house and two pharmacies located in Israel.

InterCure Ltd Provides Earnings Guidance for the First Quarter of 2021; Provides Revenue Guidance for the Second Quarter and Full Year 2021

InterCure Ltd Announces Executive Changes

Charlotte's Web, Inc. Signs Exclusive Distribution Agreement in Israel with InterCure Ltd and Canndoc Ltd

InterCure Ltd. (TASE:INCR) completed the acquisition of additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments (1996) Ltd.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines